Gastrointestinal Stromal Tumor Treatment Landscape: Market Dynamics, Therapeutic Advances, and Future Directions
Gastrointestinal Stromal Tumor Treatment: Sunitinib Malate's Role in Second-Line Therapy and Market Evolution Introduction Gastrointestinal stromal tumors, commonly known as GISTs, represent the most prevalent mesenchymal tumors of the gastrointestinal tract, though they remain relatively rare in the broader context of all cancer diagnoses. What makes GISTs clinically and commercially remarkable is the degree to which their treatment landscape has been transformed by targeted molecular therapies over the past two decades. Before the advent of precision oncology, GISTs carried a poor prognosis and responded poorly to conventional chemotherapy. Today, they are among the oncology indications most successfully treated with targeted agents, with sunitinib malate playing a pivotal role in the second-line setting. Understanding the gastrointestinal stromal tumor treatment landscape is essential not only for oncologists and gastroenterologists but also for pharmaceutical companies...